AnaptysBio, Inc. (ANAB) Reports Jemperli Sales of $1B Through September

Jemperli global net sales reached $1B through September 30, 2026; it was recently approved in the U.S. for adults with stage II and III MSI-H/dMMR locally advanced rectal cancer. Anaptys expects a litigation judgment in Q4 2026 or Q1 2027.Material DetailsContext by AI AnalystThis update combines es…